MedTrace Logo

A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma

NCT01888081 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2016-11-23

No results posted yet for this study

Summary

The purpose of this trial is to study A-dmDT390-bisFv(UCHT1) in combination with ionizing irradiation for the treatment of stage IV melanoma, a disease that is essentially incurable with median overall survival periods that range from 8-16 months.

Conditions

Interventions

DRUG

A-dmDT390-bisFv(UCHT1) (Resimmune®)

RADIATION

Ionizing Radiation

Sponsors & Collaborators

  • University of Louisville

    collaborator OTHER

  • Angimmune LLC

    lead INDUSTRY

Principal Investigators

  • Jason Chesney, MD, PhD · James Graham Brown Cancer Center, University of Louisville

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2020-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01888081 on ClinicalTrials.gov